Gene testing for all breast cancer patients with second primary malignancy, atezolizumab for TNBC, pralsetinib for NSCLC, and more
Hematology/Oncology News:
Study supports multigene panel testing for all breast cancer patients with second primary cancers: https://bit.ly/3m6RyOG
Source: https://bit.ly/2ZKXund
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results: https://bit.ly/35rqzrl
Alert: https://bit.ly/2Reh1HM
Trial: https://bit.ly/2ZqqIqX
Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz
Unexpected results in new COVID-19 ‘cytokine storm’ data: https://bit.ly/3k8fIGL
JAMA research letter: https://bit.ly/35ubxB4
You can email the show at podcasts@mdedge.com
Create your
podcast in
minutes
It is Free